drugset / Trial / NCT00812240
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
RandomizedParallel-groupOpen-labelTreatment
Summary
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
Timeline
- Start
- 2009-01
- Primary completion
- 2018-07
- Completion
- 2018-07
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision based on portfolio prioritization”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Imatinib | Small molecule | 400 mg | Oral |
| Comparator | Imatinib | Small molecule | 600 mg | Oral |
| Subject | Masitinib | Small molecule | 6 mg/kg | Oral |
| Subject | Masitinib | Small molecule | 7.5 mg/kg | Oral |